Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Hepatitis Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Hepatitis Other
    Extending PEG-IFN Alfa-2a Therapy in Patients With Chronic HBV Can Lead to HBeAg Seroconversion, HBsAg Clearance: Presented at AASLD - (DGDispatch)
    Patients Previously Treated With Adefovir Can Achieve Complete Viral Suppression When Switched to Entecavir: Presented at AASLD - (DGDispatch)
    Lamivudine, Entecavir Both Improved Prognosis in Hepatitis B-Related Acute-on-Chronic Liver Failure: Presented at AASLD - (DGDispatch)
    Adefovir Plus Lamivudine Is Effective in Patients With Lamivudine-Resistance Chronic Hepatitis B: Presented at AASLD - (DGDispatch)
    Telbivudine Safe and Effective in Suppressing Hepatitis B Over Very Long Term: Presented at AASLD - (DGDispatch)

    News archive

     Recent webcasts/CME - Hepatitis Other
      HBV-HIV Co-infection
      HBV in Pregnancy
      Debate: Monotherapy vs. Multiple Drug Therapy as the Wave of the Future for HBV Infection
      Hepatitis B Treatment: Current Best Practices How to Avoid Resistance
      Understanding Cultural Barriers

      Webcasts/CME archive

       Recent cases - Hepatitis Other
        A Familial Case of Autoimmune Hepatitis
        A 35-Year-Old Asian Man with Jaundice and Markedly High Aminotransferase Levels
        Acute Hepatitis A Virus Infection Presenting with Multiorgan Dysfunction: A Case Report
        Ceftriaxone-Induced Toxic Hepatitis
        Patient with Hepatitis B and Rheumatoid Arthritis

        Cases archive
          




        my personal edition > hepatitis other > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Adefovir Dipivoxil Increases Lasting Seroconversion in the Treatment of HBeAg-Positive Chronic Hepatitis B: Presented at AASLD

        By Maria Bishop

        BOSTON, MA -- November 3, 2006 -- In a study of patients with hepatitis e antigen (HBeAg)-positive chronic hepatitis B virus (HBV), 91% experienced lasting seroconversion of HBeAg after a median of 5 years of treatment with adefovir dipivoxil (10 mg daily) in a placebo-controlled trial, researchers reported here at the 57th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD).

        Patrick Marcellin, MD, professor, department of hepatology, Institut Nationale de la Santé et de la Recherche Médicale (INSERM) Unit 481, Hôpital Beaujon, Clichy, France, led an international team of researchers in following HBeAg-positive subjects over the course of 5 years.

        The first-year improvements during therapy, he noted, were virological, serological, and biochemical (N Engl J Med 2003; 348:808-16), with no resistance mutations detected. Patients were randomised to receive adefovir 10 mg, adefovir 30 mg, or placebo. Most patients had multiple doses of placebo in year 2 due to an error in drug allocation.

        Patients given adefovir 10 mg in year 1 who did not seroconvert in years 1 and 2 (n = 65) were allowed to continue in the long-term safety and efficacy study, with assessments every 3 months for 3 years, explained Dr. Marcellin.

        Patients were predominantly male (83%) with a median age of 34; 74% were Asian. Median serum HBV deoxyribonucleic acid (DNA) was 8.45 log10 copies/mL, and the median alanine aminotransferase (ALT) was 2.0 times the upper limit of normal (ULN).

        Upon follow-up through year 5, 38 of the 65 patients had a confirmed rebound in HBV DNA or were never fully suppressed. At 5 years, the median change from baseline in serum HBV DNA and ALT for the 41 patients still on adefovir was -4.05 log10 copies/mL and -50 U/L, Dr. Marcellin noted.

        Probabilities of HBeAg loss and seroconversion at 240 weeks were 60% and 48%, respectively. Four patients (2%) lost hepatitis B s antigen (HBsAg) and seroconverted to anti-HBs.

        Adefovir-resistant mutations A181V and/or N236T were detected in 13 of the long-term study patients (20%) beginning at week 195; 12 patients (18%) also had virologic resistance and 5 patients had clinical resistance.

        There were no serious adverse events related to adefovir.

        Dr. Marcellin concluded that these results showed positive long-term safety and efficacy in a difficult-to-treat population. Liver biopsies of 15 patients taken at baseline were compared again after long-term follow up and demonstrated improvements in necroinflammation and fibrosis in the majority of patients.


        [Presentation title: Long-term Efficacy and Safety of Adefovir Dipivoxil for the Treatment of HBeAg-Positive Chronic Hepatitis B (CHB) Patients. Poster 969]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send